Biotech and Pharma

Paramount Skydance stock rises after Warner Bros. Discovery says it will restart deal talks with the company.

Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.

Applied Materials shares surged after the semiconductor-equipment maker beat analysts’ quarterly earnings estimates.

The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain pancreatic cancers.

AppLovin and Cisco slide after reporting earnings while Fastly soars on better-than-expected quarterly profit and solid guidance.

The vaccine maker says the Food and Drug Administration has refused to review its application to sell a new seasonal flu vaccine.

Robinhood reports weaker-than-expected growth in the fourth quarter while shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.

Sales have been falling within the company’s cell-therapy portfolio.

Spotify posts significant gains in monthly active users, while CVS slips after earnings.

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.

Kyndryl’s chief financial officer, David Wyshner, departs the company amid a review of its accounting practices.

Lilly agrees to acquire Orna Therapeutics in an all-cash deal.

The test, made by California-based biotech firm Grail, promises to test for dozens of cancers.

The January jobs report is coming this week, the robot revolution is getting real, Hims & Hers backs down on Wegovy knockoff, and more news to start your day.

The initiative will offer discounted cash prices on about 40 drugs from the following manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.

Amazon shares tumble after the tech and online retailing giant forecasts $200 billion in capital expenditures for 2026.

Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.

Shares in the Danish drugmaker have tanked this week, dragged down by a weak sales outlook and the launch of a Wegovy knockoff.

The Bitcoin rout continues, one IPO pauses while three more move ahead, Hims & Hers offers knockoff Wegovy pill, and more news to start your day.

Google parent Alphabet beats analysts’ expectations for quarterly earnings and revenue but its capital spending forecasts widely top estimates.

Hims & Hers’ new alternative to Novo Nordisk’s Wegovy pill will sell for $49 for the first month and $99 a month after that.

Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.

Advanced Micro Devices stock falls sharply even as the chip maker posts better-than-expected earnings and guidance.

Unprofitable biotech Veradermics, which still needs FDA approval for its hair loss pill, surged on its debut day.